U.S. Markets close in 35 mins
  • S&P 500

    3,397.21
    -3.76 (-0.11%)
     
  • Dow 30

    27,537.07
    -148.31 (-0.54%)
     
  • Nasdaq

    11,428.06
    +69.12 (+0.61%)
     
  • Russell 2000

    1,591.70
    -13.50 (-0.84%)
     
  • Crude Oil

    39.47
    +0.91 (+2.36%)
     
  • Gold

    1,909.10
    +3.40 (+0.18%)
     
  • Silver

    24.47
    +0.05 (+0.18%)
     
  • EUR/USD

    1.1818
    +0.0004 (+0.0355%)
     
  • 10-Yr Bond

    0.7780
    -0.0230 (-2.87%)
     
  • Vix

    33.12
    +0.66 (+2.03%)
     
  • GBP/USD

    1.3056
    +0.0035 (+0.2703%)
     
  • USD/JPY

    104.4600
    -0.3750 (-0.3577%)
     
  • BTC-USD

    13,618.15
    +510.92 (+3.90%)
     
  • CMC Crypto 200

    270.08
    +8.79 (+3.36%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,485.80
    -8.54 (-0.04%)
     

Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

Zacks Equity Research

Eli Lilly & Company LLY announced plans to launch lower-priced versions of two of its insulin product, Humalog – Humalog Mix75/25 KwikPen and Humalog Junior KwikPen.

The list price of these low-priced insulin injections will be 50% lower than the current list price of the branded options. The lower-priced version of Humalog Mix75/25 will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (100 units/mL) while that of Humalog Junior KwikPen will be known as Insulin Lispro Injection Junior KwikPen. The cheaper KwikPens pack of five will cost $265.20 and are expected to be available from mid-April.

We remind investors that in May last year Lilly had launched a cheaper version of Humalog U-100 called Insulin Lispro Injection, which contains an identical molecule as Humalog. Insulin Lispro Injection was also priced 50% lower than the list price of Humalog U-100. Lilly said that since then 10% of people using Humalog have transitioned to the cheaper injection.

Lilly’s stock has risen 20.4% in the past year compared with 13.4% increase for the industry.

 

 

The move comes as the three largest insulin manufacturers, Lilly, Sanofi SNY and Novo Nordisk NVO face increasing scrutiny for steep prices of insulins. Prices have reportedly nearly doubled in the past five years. The insulin makers have defended the high list prices by saying that they have to pay significant rebates to pharmacy benefit managers to secure market share. However, uninsured patients suffer a lot due to the high list prices of insulins.

Last year, executives from several big pharma companies including Pfizer PFE, Sanofi, J&J, AbbVie and others were grilled by senators regarding high drug prices. Senators stated that the United States has some of the highest drug prices in the world and the companies need to make changes in drug pricing before the government imposes regulations. They blamed the American patent system for the high prices of drugs as it gives these companies a lot of monopoly protection.

Lilly currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.

This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Sanofi (SNY) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research